WeDoctor to Cut Workforce After Delay in Going Public, Sources Say
(Bloomberg) -- WeDoctor, one of China's leading online health-care platforms, is laying off a substantial chunk of its workforce after plans for an initial public offering were disrupted, according to people familiar with the matter.
The Tencent Holdings Ltd.-backed startup has already trimmed back to about 3,000 employees from about 4,000 last year, said the people, asking not to be identified because the details are private. WeDoctor will likely cut more jobs to a total of mid- to low- 2,000s, they said. It will also reduce base salaries and shift compensation for some people to performance-related bonuses, they said.
WeDoctor filed for a IPO in Hong Kong last year, but Beijing's sweeping crackdown on the country's private sector has disrupted many such offerings. The overhaul is aimed at repositioning the company as it explores going public via a potential merger with a special purpose acquisition company, instead of a traditional IPO, the people said. Startups face tighter listing rules, particularly if they collect sensitive data like the medical information WeDoctor handles.
In an e-mailed statement, the company said that it is optimizing its business lines and will adjust staff and salaries accordingly. The company is improving its compensation system to provide better incentives for employees.
WeDoctor had raised about $400 million in a pre-IPO round from investors including Sequoia Capital China and Millennium Management LLC at the end of 2020, Bloomberg News has reported, and had begun talking with investment bankers about the planned IPO. The company rehired Jeff Chen as chief strategy officer to look after capital markets and the listing process.
WeDoctor is part of a flock of technology companies aiming to transform China's health-care system with advanced technology. The medical platform spans insurance policies, medical supplies, online appointment-booking and clinics. The national health-care operator, which covers more than 95% of the population, is working with the firm to provide insurance-covered health care.
Read more on WeDoctor's valuation and IPO plans
©2022 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.